



## FOR IMMEDIATE RELEASE

### Company Contacts:

#### Nuvectra Corporation

Walter Berger, Chief Financial Officer  
(972) 668-4106  
wberger@nuvectramed.com

Jennifer Armstrong, Media Relations  
(214) 618-4823  
jarmstrong@nuvectramed.com

### Investor Contacts:

#### The Ruth Group

Nick Laudico  
(646) 536-7030  
nlaudico@theruthgroup.com

Zack Zubow  
(646) 536-7020  
zkubow@theruthgroup.com

## Nuvectra to Report Fourth Quarter 2016 Financial Results on March 7, 2017

**Plano, Texas, February 21, 2016** – Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter ended December 30, 2016 on Tuesday, March 7, 2017 before the market open.

Nuvectra will hold a conference call on Tuesday, March 7, 2017 at 8:30am ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 69290765. A live webcast of the conference call will be available on the investor relations section of the Company's website at <http://investors.nuvectramed.com/>.

A replay of the call will be available starting on March 7, 2017 through March 14, 2017. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 69290765. The webcast will be available in the investor relations section of the Company's website for 90 days following the completion of the call.

### About Nuvectra Corporation

Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at [www.nuvectramed.com](http://www.nuvectramed.com).